NCT06805851 Impact of Depression on Thermoregulation
| NCT ID | NCT06805851 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Penn State University |
| Condition | Depression |
| Study Type | OBSERVATIONAL |
| Enrollment | 64 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 64 participants in total. It began in 2025-03-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if, compared to non-depressed adults, differences exist in skin blood flow and sweating responses to passive heat stress in adults with clinically diagnosed depression, those with depression who are prescribed and taking SSRIs and those with depression who are prescribed and taking SNRIs.
Eligibility Criteria
Inclusion Criteria: * Non-depressed adults aged 18-40 years; * OR adults aged 18-40 years with clinically diagnosed major depressive disorder according to DSM-V criteria not currently receiving antidepressant treatment; * OR adults aged 18-40 years with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a selective serotonin reuptake inhibitor; * OR aged 18-40 years adults with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a serotonin norepinephrine reuptake inhibitor; * All participants will be asymptomatic and no signs/symptoms of disease according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription (chest pain or pressure, dizziness, joint pain, and signs of cardiovascular disease); * Systolic blood pressure 140 mmHg and diastolic pressure 90 mmHg at screening; * Non-diabetic * Not taking any other medications that might affect the physiological variables of interest (beta blockers, tricyclic antidepressants, antipyretics, diuretics, etc.);; * Between the 20th and 80th percentiles for sex- and age-appropriate VO2max according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription; * English proficiency; * Capable of providing informed consent. Exclusion Criteria: * BMI \> 35 * Are pregnant or planning to become pregnant in the next 12 months; * Concurrently participate in another study involving physical activity or weight loss; * Plan to have surgery or relocate outside the area within the next year; * Medications that could alter cardiovascular or thermoregulatory responses to exercise (beta blockers, antipyretics, tricyclic antidepressants, diuretics, etc.); * Allergy to latex or adhesive; * Tobacco use; * Illegal/recreational drug use; * Exertional chest pain or musculoskeletal pain; * Contraindications to a maximal exercise test or an indication for early termination of the exercise test according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription; * Abnormal resting or exercise electrocardiogram (ECG); * Any bleeding disorders, gastric ulcers, allergies to NSAIDS, asthma, kidney/liver disorders, and taking any other anticoagulants; * History of Crohn's disease, diverticulitis, or similar gastrointestinal disease; * Co-morbid psychiatric disorders (psychosis, schizophrenia, bipolar disorder, panic disorder, obsessive compulsive disorder, etc.); * Active suicidal ideation (moderate or high suicidality); * Use of psychoactive or psychopharmacological drugs other than SSRI and SNRIs within one year of participating.
Contact & Investigator
W. Larry Kenney
PRINCIPAL INVESTIGATOR
The Pennsylvania State University
Frequently Asked Questions
Who can join the NCT06805851 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06805851 currently recruiting?
Yes, NCT06805851 is actively recruiting participants. Contact the research team at w7k@psu.edu for enrollment information.
Where is the NCT06805851 trial being conducted?
This trial is being conducted at University Park, United States.
Who is sponsoring the NCT06805851 clinical trial?
NCT06805851 is sponsored by Penn State University. The principal investigator is W. Larry Kenney at The Pennsylvania State University. The trial plans to enroll 64 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.